Synchronous Parotid (Mammary Analog) Secretory Carcinoma and Acinic Cell Carcinoma: Report of a Case

Mossinelli, Chiara; Pigni, Carolina; Sovardi, Fabio; Occhini, Antonio; Preda, Lorenzo; Benazzo, Marco; Morbini, Patrizia; Pagella, Fabio

doi:10.1007/s12105-018-0935-1

Cited by 9 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Out of a total of 226 studies published between 2010 and 2023, identified at initial search and screened for retrieval, 112 1–3,6–114 articles were included in the study, with a total of 674 patients described in these articles. The identification and screening process is described in Figure 1.…”

Section: Resultsmentioning

confidence: 99%

Salivary Gland Secretory Carcinoma; Review of 13 Years World‐Wide Experience and Meta‐Analysis

Yosefof,

Boldes,

Dan

et al. 2023

The Laryngoscope

View full text Add to dashboard Cite

ObjectivesSecretory Carcinoma is a malignant salivary gland tumor, initially described in 2010. This rare tumor is associated with the translocation t(12;15) (p13;q25), resulting in the fusion gene ETV6‐NTRK3. Since this tumor is quite rare, most publications describe only small cohorts of patients. We aimed to investigate the clinical, pathological, and prognostic features of this newly defined malignant entity.Data SourcesPubmed, Google Scholar, and Web of Science databases.Review MethodsAll published articles between 2010 and 2023 were reviewed. Search terms included the terms “Mammary Analogue Secretory Carcinoma” and “Secretory Carcinoma”. All articles published in English reporting on Secretory Carcinoma of salivary glands were retrieved.ResultsOne‐hundred and 12 retrospective articles reporting a total of 674 patients were included, with 52% males and a mean age of 44.9 ± 18.9. The event rate for patients with advanced‐stage disease (Stage 3/4) at presentation was 24.1% (95% CI 17.6%–31.9%, I2 = 9.2%), 14.6% for regional metastases (95% CI 10.5%–20%, I2 = 12%), and the event rate of distant metastasis was 8.4% (95% CI 5.5%–12.7%, I2 = 4.2%). Adjuvant radiotherapy was administered for 30.3% of patients (95% CI 24.1%–37.2%, I2 = 21.5%). The recurrence rate was 19% (95% CI 15.1%–23.8%, I2 = 5%). Survival outcomes showed a 17.2% death of disease rate for Secretory Carcinoma patients (95% CI 13.5%–21.8%, I2 = 7.3%).ConclusionsSecretory Carcinoma is a rare and relatively newly defined entity arising in the parotid gland most commonly. Characterized as a low‐grade tumor, the majority of patients are diagnosed at an early stage, without regional or distant disease, and the prognosis is relatively good.Level of EvidenceN/A Laryngoscope, 2023

show abstract

Section: Resultsmentioning

confidence: 99%

Salivary Gland Secretory Carcinoma; Review of 13 Years World‐Wide Experience and Meta‐Analysis

Yosefof,

Boldes,

Dan

et al. 2023

The Laryngoscope

View full text Add to dashboard Cite

show abstract

“…For instance, unlike AciCCs, SCSGs have no secretory zymogen cytoplasmic granules that undergo true positive periodic acid–Schiff reactions 17 . Additionally, the nuclei of SCSGs have prominent pseudo-inclusion bodies; however, SCSGs do not contain other cell types, such as serous, intermediate, and clear cells, which are commonly observed in AciCCs 18 . As for immunophenotypes, SCSGs can express various markers of breast secretory carcinomas, including mammaglobin, S-100 protein, STAT5A, MUC1, MUC4, GCDFP-15, CK7, CK8, CK18, CK19, and epithelial cell membrane proteins 19 .…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological characteristics and outcomes of 23 patients with secretory carcinoma of major salivary glands

Sun

Liu

et al. 2021

Sci Rep

View full text Add to dashboard Cite

This retrospective study investigated the clinicopathological characteristics of secretory carcinoma of salivary glands (SCSG) in 23 patients with histopathologically confirmed SCSG between January 2010 and December 2020. In total, 13 males and 10 females (ratio, 1.3:1) aged 10 − 69 years (median, 45 years) were enrolled in this study; the average disease duration was 2.44 years (0.25–20 years). Twenty-one patients (91.3%) had SCSG in the parotid gland, and two (8.7%) in the submandibular gland. All patients had single nodules of diameters 0.8–4.8 cm (average 2.6 cm); five with lymph node metastases, and two with distant metastases. Immunohistochemically, tumors stained positive for S-100, mammaglobin, CK7, GATA3 and pan-Trk, and negative for DOG1, P63, and calponin, with Ki-67 positivity from 1 to 50%. ETV6 gene rearrangement was confirmed in 15 patients. All patients underwent oncological resection, four had radioactive particles implanted postoperatively, one received chemotherapy, and seven underwent chemoradiotherapy. Six patients had regional recurrences, two distant metastases, and one died before the last follow-up. SCSGs are typically indolent, with a low locoregional recurrence rate and excellent survival. Prognosis is correlated to clinical stage, pathological grade, and surgical procedures.

show abstract

“…Unlike ACCs, SCSGs have no secretory zymogen cytoplasmic granules that show true positive periodic acid-Schiff reactions [15]. The nuclei of SCSGs have prominent pseudo-inclusion bodies and SCSGs do not have the other cell types, such as serous, intermediate, and clear cells, that are seen in ACCs [16]. As to immunophenotypes, SCSGs can express various markers of breast secretory carcinomas, including mammaglobin, S-100 protein, STAT5A, MUC1, MUC4, GCDFP-15, as well as CK7, CK8, CK18, CK19, and epithelial cell membrane proteins [17].…”

Section: Discussionmentioning

confidence: 99%

“…The degree of enhancement varied, mostly being uneven and marked (> 40 HU). However, a few tumors showed mild enhancement (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20) or no obvious enhancement (< 10 HU). Most of the recurrences showed marked enhancement.…”

Section: Imaging Ndingsmentioning

confidence: 99%

Clinicopathological characteristics and outcomes of 23 patients with secretory carcinoma of major salivary glands

Sun

Liu

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Secretory carcinoma of salivary glands (SCSGs) are generally low-grade salivary gland carcinomas, and are characterized by morphological resemblance to mammary analogue secretory carcinoma and ETV6–NTRK3 gene fusion. Several reports on histopathological features of SCSG have recently been published; however, little is known about the clinical characteristics of this new tumor, including its outcomes. The research is to investigate the clinicopathological characteristics of secretory carcinoma of major salivary glands and to analyze outcomes of these carcinomas as a reference for standardizing their diagnosis and treatment. Methods The cohort of this retrospective study comprised 23 patients treated for histopathologically-confirmed SCSG between January 2010 and December 2020. Their clinical characteristics and outcomes were retrieved from patient files. Results The 23 patients comprised 13 male and 10 female patients (male:female ratio 1.3:1). They were aged 10–69 years (median 45 years) and the average duration of disease was 2.44 years (0.25–20 years). Twenty-one patients (91.3%) had SCSGs in the parotid gland and two (8.7%) in the submandibular gland. All 23 patients had single nodules with diameters of 0.8–4.8 cm (average 2.6 cm). Five patients had lymph node metastases and two had distant metastases. All tumors were pathologically diagnosed as SCSGs. Immunohistochemical staining was strongly positive for S-100, mammaglobin, CK7, and Gata3, and negative for Dog1, P63 and calponin. Ki-67 positivity ranged from 1–50%. Fluorescence in situ hybridization data were available for 15 patients, in all of whom ETV6 gene rearrangement was confirmed. All patients had undergone oncological resections. Four had radioactive particles implanted postoperatively, one received chemotherapy, and seven underwent chemoradiotherapy. Six patients had regional recurrences, two distant metastases, and one had died at the time of last follow-up. Conclusions SCSGs are typically indolent with a low rate of locoregional recurrence and excellent survival. Their prognosis is correlated with clinical stage, pathological grade, and surgical procedures performed.

show abstract

Synchronous Parotid (Mammary Analog) Secretory Carcinoma and Acinic Cell Carcinoma: Report of a Case

Cited by 9 publications

References 35 publications

Salivary Gland Secretory Carcinoma; Review of 13 Years World‐Wide Experience and Meta‐Analysis

Salivary Gland Secretory Carcinoma; Review of 13 Years World‐Wide Experience and Meta‐Analysis

Clinicopathological characteristics and outcomes of 23 patients with secretory carcinoma of major salivary glands

Clinicopathological characteristics and outcomes of 23 patients with secretory carcinoma of major salivary glands

Contact Info

Product

Resources

About